These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 28633480)

  • 1. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
    Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.
    Tong B; Xu Y; Zhao J; Chen M; Zhong W; Xing J; Wang M
    Thorac Cancer; 2018 May; 9(5):640-645. PubMed ID: 29582563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
    Tan CL; Lim TH; Lim TKh; Tan DS; Chua YW; Ang MK; Pang B; Lim CT; Takano A; Lim AS; Leong MC; Lim WT
    Oncotarget; 2016 Apr; 7(17):23251-62. PubMed ID: 26993609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
    Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
    Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
    J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
    Bian J; Yan K; Liu N; Xu X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer.
    Li J; Liao Y; Ran Y; Wang G; Wu W; Qiu Y; Liu J; Wen N; Jing T; Wang H; Zhang S
    BMC Pulm Med; 2020 Oct; 20(1):274. PubMed ID: 33081780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor Cells with Aberrant
    Pailler E; Oulhen M; Borget I; Remon J; Ross K; Auger N; Billiot F; Ngo Camus M; Commo F; Lindsay CR; Planchard D; Soria JC; Besse B; Farace F
    Cancer Res; 2017 May; 77(9):2222-2230. PubMed ID: 28461563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
    Yang B; Qin A; Zhang K; Ren H; Liu S; Liu X; Pan X; Yu G
    Oncol Res; 2017 Nov; 25(9):1601-1606. PubMed ID: 28474575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Papadaki MA; Messaritakis I; Fiste O; Souglakos J; Politaki E; Kotsakis A; Georgoulias V; Mavroudis D; Agelaki S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
    Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.
    Wang Y; Liu Y; Zhang Z; Lu B; Gao Y; Tong L; Hu M; Lin PP; Li B; Zhang T
    BMC Cancer; 2023 Jun; 23(1):578. PubMed ID: 37349714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.
    Yu XM; Wu YC; Liu X; Huang XC; Hou XX; Wang JL; Cheng XL; Mao WM; Ling ZQ
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.
    Juan O; Vidal J; Gisbert R; Muñoz J; Maciá S; Gómez-Codina J
    Clin Transl Oncol; 2014 Jul; 16(7):637-43. PubMed ID: 24217975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.
    Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH
    Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.